MedTrace Logo

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

NCT03085719 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-02-25

Study results available
· View outcomes & findings →

Summary

This research study is studying immunotherapy in combination with radiation therapy as a possible treatment for head \& neck cancer that has worsened or spread to another organ or part of your body.

The immunotherapy involved in this study is: MK-3475 (pembrolizumab or KEYTRUDA).

Conditions

Interventions

DRUG

Pembrolizumab

Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells

RADIATION

Radiation

Radiation is used to shrink the cancer

Sponsors & Collaborators

Principal Investigators

  • Jonathan D. Schoenfeld, MD MPH · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-30
Primary Completion
2022-11-01
Completion
2027-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03085719 on ClinicalTrials.gov